ACE D/I polymorphism, migraine, and cardiovascular disease in women

Neurology

Volumn 72, Issue 7, 2009, Pages 650-656

  Schurks M ^a   Zee, R Y L ^a   Buring, J E ^a,b,c   Kurth, T ^a,b,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; DIPEPTIDYL CARBOXYPEPTIDASE; ACE PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIGRAINE; MIGRAINE AURA; NEOPLASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MIGRAINE WITH AURA; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; MIGRAINE WITH AURA; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; SEQUENCE DELETION; WOMEN'S HEALTH;

EID: 61849143774     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000342517.97178.f6     Document Type: Article

References (37)

1. Ligthart L, Boomsma DI, Martin NG, Smbbe JH, Nyholt DR. Migraine with aura and migraine without aura are not distinct entities: further evidence from a large Dutch population study. Twin Res Hum Genet 2006;9:54-63.
2. Mulder EJ, Van Baal C, Gaist D, et al. Genetic and environmental influences on migraine: a twin study across six countries. Twin Res 2003;6:422-431.
3. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003;4:386-398.
4. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006;296:283-291.
5. Kurth T, Schiirks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 2008;337:a636.
6. Pezzini A, Grassi M, Del Zotto E, et al. Migraine mediates the influence of C677T MTHFR genotypes on ischemic stroke risk with a stroke-subtype effect. Stroke 2007;38: 3145-3151.
7. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322:19-22.
8. Nilsson PM. Optimizing the pharmacologic treatment of hypertension: BP control and target organ protection. Am J Cardiovasc Drugs 2006;6:287-295.
9. Kara I, Ozkok E, Aydin M, et al. Combined effects of ACE and MMP-3 polymorphisms on migraine development. Cephalalgia 2007;27:235-243.
10. Lea RA, Ovcaric M, Sundholm J, Solyom L, Macmillan J, Griffiths LR. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res Mol Brain Res 2005;136:112-117.
11. Lin JJ, Wang PJ, Chen CH, Yueh KC, Lin SZ, Harn HJ. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta Neurol Taiwan 2005; 14:120-125.
12. Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008;8:4.
13. Kowa H, Fusayasu E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett 2005:374:129-131.
14. Paterna S, Di Pasquale P, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000;43:133-136.
15. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004:61:1652-1661.
16. Ariyaratnam R, Casas JP, Whittaker J, Smeeth L, Hingorani AD, Sharma P. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med 2007; 4:e131.
17. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psychiatry 1998;64:227-230.
18. Morgan TM, Coffey CS, Krumholz HM. Overestimation of genetic risks owing to small sample sizes in cardiovascular studies. Clin Genet 2003:64:7-17.
19. Sayed-Tabatabaei FA, Schut AF, Vasquez AA, et al. Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. J Med Genet 2005:42:26-30.
20. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 2000; 9:19-27.
21. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304.
22. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain: Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8 suppl 7:1-96.
23. Atiya M, Kurth T, Berger K, Buring JE, Kase CS. Interob-server agreement in the classification of stroke in the Women's Health Study. Stroke 2003;34:565-567.
24. Cheng S, Grow MA, Pallaud C, et al. A multilocus geno-typing assay for candidate markers of cardiovascular disease risk. Genome Res 1999;9:936-949.
25. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005;366:1121-1131.
26. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205.
27. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Na-kashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007;128:209-214.
28. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86: 1343-1346.
29. Jakobsson M, Scholz SW, Scheet P, et al. Genotype, hap-lotype and copy-number variation in worldwide human populations. Nature 2008;451:998-1003.
30. Methot J, Hamelin BA, Bogaty P, Arsenault M, Plante S, Poirier P. ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women. Int J Cardiol 2005;105:308-314.
31. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005;330:63.
32. Schürks M, Zee RY, Buring JE, Kurth T. Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. Neurology 2008;71: 505-513.
33. Spence J. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830-838.
34. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-1219.
35. Tietjen EG. Migraine and ischaemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia 2007;27:981-987.
36. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657.
37. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-542.